Generate Biomedicines utilizes generative biology and machine learning to design and produce novel therapeutic proteins, including antibodies and enzymes, with high precision and efficiency. The platform addresses the limitations of traditional drug discovery by enabling on-demand generation of medicines tailored to specific therapeutic functions, significantly accelerating the development process.
Funding
$693M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods often face limitations in efficiently designing and producing novel therapeutic proteins, such as antibodies and enzymes, tailored to specific therapeutic functions. This can result in slow development processes and a restricted range of potential drug candidates.
Solution
Generate Biomedicines leverages generative biology and machine learning to overcome these limitations by enabling the on-demand creation of medicines with specific therapeutic functions. Their platform analyzes millions of proteins to learn the underlying rules that govern their function, and then uses these learned rules to generate novel medicines. This approach allows for the rapid design and production of a wide range of therapeutic proteins, including antibodies, peptides, and enzymes, with unprecedented speed and success rates. The platform represents a fundamental shift in drug discovery, moving beyond traditional methods to a more efficient and targeted approach.
Target Audience
The primary audience includes pharmaceutical companies and research institutions seeking to accelerate drug discovery and develop novel protein-based therapeutics.
Features
- Machine learning-driven protein design for on-demand generation of novel therapeutics
- Capability to generate antibodies, peptides, enzymes, and stealth proteins
- Analysis of millions of proteins to learn generalizable rules of function
- Platform enables rapid design and production of therapeutic proteins